Gene test may predict who benefits from asthma drug

NCT ID NCT03694158

Ongoing Disease control Sponsor: Boston Children's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether people aged 12 and older with a certain gene variant (IL-4RαR576) respond better to the asthma drug dupilumab. 150 participants will receive either dupilumab or a placebo for 48 weeks. The main goal is to see if the drug reduces asthma attacks more in those with the gene variant.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Dupilumab (Dupixent®)
What this could lead to: If successful, this could show that people with the IL-4RαR576 gene variant get better asthma control from dupilumab, leading to more personalized treatment.
What could go wrong: This is a Phase 4 trial, but results may not apply to everyone with asthma. The benefit may be small or not significant, and dupilumab can cause side effects like injection reactions or infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTHMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ASTHMA

Contacts and locations

Locations

Boston Children's Hospital

Boston, Massachusetts, 02115, United States
Brigham and Women's Hospital

Boston, Massachusetts, 02115, United States
Henry Ford Health System

Detroit, Michigan, 48202, United States
MetroHealth System

Cleveland, Ohio, 44109, United States
Montefiore Einstein Clinical Research Center

The Bronx, New York, 10467, United States
University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.